

## The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in $\beta$ -tubulin

Yang Jianhong<sup>1</sup>, Yan Wei<sup>1</sup>, Yu Yamei<sup>1</sup>, Wang Yuxi<sup>1</sup>, Yang Tao<sup>1</sup>, Xue Linlin<sup>1</sup>, Yuan Xue<sup>1</sup>, Long Caofeng<sup>2</sup>, Liu Zuowei<sup>2</sup>, Chen Xiaoxin<sup>2</sup>, Hu Mengshi<sup>1</sup>, Zheng Li<sup>1</sup>, Qiu Qiang<sup>1</sup>, Pei Heying<sup>1</sup>, Li Dan<sup>1</sup>, Wang Fang<sup>1</sup>, Bai Peng<sup>1</sup>, Wen Jiaolin<sup>1</sup>, Ye Haoyu<sup>1</sup> and Chen Lijuan<sup>1\*</sup>

From the <sup>1</sup>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China; <sup>2</sup>Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan, Guangdong 523325, China

Running title: *MDs irreversibly bind to colchicine site*

\*To whom correspondence should be addressed: Tel.:86-028-85502796;Fax: 86-02885164060;  
Email:chenlijuan125@163.com;

**Keywords:** tubulin, microtubule, colchicine, millepachine, chalcone, irreversible binding, *s-trans* conformation, drug resistance, anticancer drug, crystal structure.

## Abstract

Inhibitors that bind to the paclitaxel- or vinblastine-binding sites of tubulin have been part of the pharmacopoeia of anticancer therapy for decades. However, tubulin inhibitors that bind to the colchicine-binding site are not used in clinical cancer therapy, because of their low therapeutic index. To address multidrug resistance to many conventional tubulin-binding agents, numerous efforts have attempted to clinically develop inhibitors that bind the colchicine-binding site. Previously, we have found that millepachine (MIL), a natural chalcone-type small molecule extracted from the plant *Millettia pachycarpa*, and its two derivatives (MDs) SKLB028 and SKLB050 have potential antitumor activities both *in vitro* and *in vivo*. However, their cellular targets and mechanisms are unclear. Here, biochemical and cellular experiments revealed that the MDs directly and irreversibly bind  $\beta$ -tubulin. X-ray crystallography of the tubulin–MD structures disclosed that the MDs bind at the tubulin intradimer interface and to the same site as colchicine and that their binding mode is similar to that of colchicine. Of note, MDs inhibited tubulin polymerization and caused G2/M cell cycle arrest. Comprehensive analysis further revealed that free MIL exhibits an *s-cis* conformation, whereas MIL in the colchicine-binding site in tubulin adopts an *s-trans* conformation. Moreover, introducing an  $\alpha$ -methyl to MDs in order to increase the proportion of *s-trans* conformations augmented MDs' tubulin inhibition activity. Our study uncovers a new class of chalcone-type tubulin inhibitors that bind the colchicine-binding site in  $\beta$ -tubulin and suggests that the *s-trans* conformation of these compounds may make them more active anticancer agents.

## Introduction

Microtubules are formed by non-covalent tubulin heterodimers ( $\alpha$ - and  $\beta$ -tubulin), in a process that involves polymerization and depolymerization (1). Microtubules play important roles in key cell events especially in mitosis and this makes them an

attractive target for anti-cancer drug design (2). Currently, many microtubule inhibitors (MTIs) such as taxanes, *Vinca* alkaloids and epothilones are used against many solid and hematologic malignancies (3-5). Although the MTIs have been demonstrated to exert a high level of anti-cancer activity in clinical treatment or preclinical testing, their effectiveness is limited by multidrug resistance, peripheral neuropathy and insolubility (6,7). Membrane efflux pumps of the ATP-binding cassette (ABC) family are the primary resistance mechanism developed by tumor cells exposed to microtubule-binding agents (8,9).

Colchicine was the first identified tubulin destabilizing agent (10), and is commonly used as an unapproved drug to treat gout, familial Mediterranean fever, pericarditis and Behçet's disease (11-14). In 2009, the FDA approved colchicine to treat acute gout flares and familial Mediterranean fever. Although colchicine was not approved to treat cancer, due to its low therapeutic index, numerous efforts were made to clinically develop colchicine binding site inhibitors (CBSIs), because the favorable factors of most CBSIs are that they have no multidrug resistance (MDR) issues, they have a simple structure, and they are easy to synthesize(15).

Recently research revealed that another possible way to overcome MDR is to develop irreversible binding agents as suggested by Buey *et al*, who showed that cyclostreptin, a natural small molecule, retains its activity in cells that are resistant to paclitaxel by overexpression of P-glycoprotein through covalently (irreversibly) binding to Thr220 and Asn228 of  $\beta$ -tubulin(16). The authors proposed the idea that resistant tumor cells cannot escape the effect of compounds irreversibly binding to them by reducing their affinity for the target or by enhancing drug efflux, which suggests that the design of ligands that irreversibly react with tubulin might be an effective way to address drug resistance. For instance, zampanolide and (+)-dactylolide, new microtubule-stabilizing agents, retain full activity in

MDR cell lines by covalently (irreversibly) binding to the taxane luminal site in  $\beta$ -tubulin(17,18). T138067, a tubulin inhibitor that acts by covalent modification of  $\beta$ -tubulin residue Cys-239, retains full activity in MDR cells both *in vitro* and *in vivo* (19). Recently, Murray *et al* showed that irreversible mitotic blockade and persistent drug retention served as a good explanation for the excellent anti-cancer activity of eribulin on drug resistant cell lines(20). All these findings proved that irreversible modification of tubulin may overcome MDR driven by ABC pumps.

Millepachine (MIL) was first isolated from *Millettia pachycarpa* Benth by our group (21). Our following study showed this novel chalcone possessed anti-cancer activity by inducing cell cycle G2/M arrest and apoptosis in human hepatocarcinoma cells (22). Through modification of MIL we achieved the derivatives SKLB028 and SKLB050 with low nanomolar  $IC_{50}$ s to various tumor cells including drug-resistant cell lines (Fig. 1A), with obvious improved anti-cancer activities compared to MIL(23,24). SKLB050 could circumvent multidrug resistance in a A2780CP (P-glycoprotein overexpression) model (24). In our present study, through biotinylation of MIL and structural biology studies, we found that MIL and its derivatives (MDs) could irreversibly bind to the colchicine site of  $\beta$ -tubulin and retained full activity toward MDR cells. Deeper mechanistic study revealed that free MIL adopts an *s-cis* conformation but is in an *s-trans* conformation in the colchicine site, and that introducing an  $\alpha$ -methyl to MDs to increase the proportion of *s-trans* conformations could clearly augment the activity of MDs.

## Results

### *MIL directly binds to tubulin*

In our previous study, MIL and its derivatives, SKLB028 and SKLB050 (Fig. 1A), showed an effect on tubulin polymerization, and this prompted us to identify the potential targets of these compounds. For this purpose, the chemical probe biotin-tagged SKLB028 (hereafter named Bio-SKLB028) was synthesized (Fig. S1). Bio-SKLB028 retained full activity toward cancer cells in comparison with free

SKLB028 (Table 1). Next, HepG2 cell lysates were incubated with Bio-SKLB028 or free biotin, and the mixtures were precipitated with streptavidin-coated agarose beads, followed by gel electrophoresis and coomassie blue staining. We observed one major protein band that co-precipitated specifically with Bio-SKLB028-beads, with an apparent molecular size of 55 kDa, whereas the biotin-beads produced no such bands (Fig. 1B). MS data revealed that the specific band is mostly like  $\beta$ -tubulin (Fig. S2). Also, the specific band co-migrated with  $\alpha$ - and  $\beta$ -tubulin, as determined by western blot analysis (Fig. 1C). Bio-SKLB028 also bound the *in vitro* porcine tubulin proteins in a concentration-dependent manner, but this binding was competitively inhibited by higher concentrations of unlabeled SKLB028 (Fig. 1D). Also, this binding of SKLB028 to tubulin was time-dependent (Fig. 1E). Changes in tryptophan fluorescence of tubulin were used as a test for drug binding(25). Using this tryptophan-based binding assay, as shown in Fig. 1F, we identified the  $K_d$  (dissociation constants) values of compounds binding to tubulin were  $5.13 \pm 0.62 \mu\text{M}$  (SKLB050),  $11.03 \pm 2.57 \mu\text{M}$  (colchicine),  $31.69 \pm 5.26 \mu\text{M}$  (SKLB028), and  $139.3 \pm 34.76 \mu\text{M}$  (MIL). All these results together proved that MIL directly binds to tubulin.

### **MDs inhibit tubulin polymerization and induce G2/M phase cell-cycle arrest**

We further investigated the effect of MIL, SKLB028, and SKLB050 on tubulin inside the cells by immunofluorescence staining. As shown in Fig. 2A, colchicine inhibited tubulin polymerization while paclitaxel obviously promoted tubulin polymerization in HCT-8/V cells. MDs inhibited tubulin polymerization in a colchicine-like manner. Furthermore, SKLB028 inhibited tubulin polymerization in a time- and dose-dependent manner. We further evaluated the effects of MDs on tubulin *in vitro*. The effects on the assembly of purified porcine tubulin were evaluated by measuring an increase in absorbance at 340 nm at 37 °C, by using colchicine and paclitaxel as comparative agents. Similar to colchicine, we found that SKLB028 and SKLB050 inhibited tubulin

polymerization, and MIL showed a weak tubulin polymerization inhibition effect (Fig. 2B). We then investigated the effect of MDs on the cell cycle. As shown in Fig. 2C, we found that MDs could obviously increase the expression level of p-H3 (a G2/M phase marker), and the flow cytometry results also showed that MDs could cause obvious G2/M phase arrest (Figs 2D and S3). In all, MDs could inhibit tubulin polymerization and cause subsequent G2/M cell cycle arrest.

#### ***MDs bind to the colchicine site of $\beta$ -tubulin***

To identify the binding site of MDs on tubulin, a competition experiment between Bio-SKLB028 with SKLB028, vinblastine, colchicine and SKLB050 was performed. Porcine tubulin (1  $\mu$ M) was pre-incubated with SKLB028 (10  $\mu$ M), vinblastine (1 or 10  $\mu$ M), colchicine (1 or 10  $\mu$ M), or SKLB050 (10  $\mu$ M) for 1 h before treating with Bio-SKLB028 (10  $\mu$ M) for 2 h. Then the proteins were thoroughly washed and detected by western blotting for biotin. As shown in Fig. 3A, SKLB028 and SKLB050 could inhibit the binding of Bio-SKLB028 to tubulin, which indicated that SKLB028, SKLB050, and Bio-SKLB028 bind to the same site on tubulin. Vinblastine showed no inhibition of the binding of SKLB028 to  $\beta$ -tubulin, whereas 1  $\mu$ M colchicine weakly inhibited the binding of SKLB028 to  $\beta$ -tubulin and 10  $\mu$ M colchicine strongly inhibited the binding of SKLB028 to tubulin. These data proved that MDs bind to the colchicine site of  $\beta$ -tubulin. Next, N,N'-ethylene-bis(iodoacetamide) (EBI), a homobifunctional thioalkylating agent, was used to crosslink the Cys-239 and the Cys-354 residues of  $\beta$ -tubulin involved in the colchicine-binding site (26). The covalent binding of EBI to  $\beta$ -tubulin forms an adduct that is easily detected by western blotting as a second immunoreactive band of  $\beta$ -tubulin that migrates faster than the native  $\beta$ -tubulin band on SDS-PAGE(26). To comprehensively validate the binding of MDs to the colchicine site on  $\beta$ -tubulin, we detected whether MDs could inhibit the binding of EBI to  $\beta$ -tubulin. Our results showed that MIL and SKLB028 at high doses and SKLB050 at moderate and high doses could inhibit the formation

of EBI- $\beta$ -tubulin adducts (Fig. 3B). These results also indicated that MDs bind to the colchicine site of  $\beta$ -tubulin.

#### ***SKLB028 and SKLB050 were effective on MDR tumor cells.***

Next, we tested the anti-tumor activity of SKLB028 and SKLB050 on drug-resistant cells. A2780S, HCT-8 tumor cells and three related drug-resistant cell lines expressing high levels of P-Pg170 or MRP1 (Fig. S4) were treated with SKLB028 or SKLB050 for 48 h. As shown in Table 2, SKLB028 and SKLB050 showed strong and similar growth inhibition against both sensitive and MDR cell lines, with a resistance factor ranging from 1.5 to 2.5, as compared with resistance factors of 186–733 for paclitaxel and vinblastine.

#### ***SKLB028 binds irreversibly to tubulin***

As MIL and its derivatives strongly bind to  $\beta$ -tubulin, we tried to detect whether these compounds bind irreversibly to tubulin. Tubulin was incubated with SKLB028 or colcemid (a reversible tubulin inhibitor), and then separated by an ultrafiltration method. Compounds in the tubulin and filtrate fractions were detected by HPLC. Controls showed that SKLB028 and colcemid should have been detectable. In the colcemid-treated group, colcemid was detected in both the tubulin fraction and the filtrate fraction. In contrast, in the SKLB028-treated group, the tubulin fraction was devoid of SKLB028, and SKLB028 in the filtrate fraction was greatly reduced following incubation of SKLB028 with tubulin (Fig. 4A). In the absence of degradation products, SKLB028 must have reacted irreversibly with tubulin.

Similarly, there were differences in the effects of SKLB028 and colcemid on cellular tubulin. HCT-8/V cells were treated with high concentrations (10  $\mu$ M) of SKLB028 or colcemid for 8 h; then the cells were extensively washed to remove compounds and were further cultured to 72 h. At 0, 8, 24, 48 and 72 h points, tubulin morphology and cell cycle were analyzed by immunofluorescence and flow cytometry, respectively. We observed recovery of the tubulin network in colcemid-treated cells. However, the

effects of SKLB028 were irreversible. As shown in Fig. 4B, cells had typical tubulin networks at 0 h. After incubation with SKLB028 or colcemid for 8 h, the tubulin began to depolymerize and a small portion of cells were arrested at G2/M phase, as indicated by abnormal (asymmetric and multipolar) spindles marked by  $\gamma$ -tubulin. After washing and another 16 h in culture, the depolymerization and G2/M phase arrest effect of SKLB028 had progressed, resulting in almost complete loss of the tubulin network. Also, more cells with abnormal spindles were observed. With colcemid, the tubulin network began to revert to a normal appearance. After a 40-h recovery, SKLB028-treated cells remained the same, with depolymerized tubulin and abnormal spindles. After 40 h without drug exposition, colcemid-treated cells had almost recovered to normal. After recovery for 64 h, SKLB028-treated cells showed the same morphology as those at 40 h, but the colcemid-treated cells showed typical microtubule networks again.

We also examined the HCT-8/V cells for DNA content by flow cytometry (Figs S5 and S6), and these data also indicated a greater recovery after colcemid versus SKLB028 treatment, with a larger population of G2/M cells persisting after the SKLB028 treatment. All these results proved that SKLB028 binds irreversibly to tubulin.

#### ***X-ray crystal structure of the tubulin complex with MIL, SKLB028 or SKLB050***

To obtain the detailed interaction of MIL and its derivatives with tubulin, we solved the crystal structure of tubulin-MIL, tubulin-SKLB028 and tubulin-SKLB050 complexes. Compounds were soaked into a well-established crystallization system based on a protein complex composed of two  $\alpha\beta$ -tubulin heterodimers, one stathmin-like protein RB3 and one tubulin tyrosine ligase (T2R-TTL) (18,27). With this method, we determined the tubulin-MIL (PDB:5YLJ), tubulin-SKLB028 (PDB:5YL2) and tubulin-SKLB050 (PDB:5YLS) structures to a resolution of 2.70, 2.09 and 3.00 Å, respectively. Data collection and refinement statistics are given

in Table 3. In general, there are no big changes in the overall structures of the three complexes when compared to the apo-tubulin structure (PDB:5XP3). In the MIL-tubulin structure, MIL occupied a pocket formed by residues from helices H7 and H8, strands S8 and S9 and loop T7 of  $\beta$ -tubulin and of loop T5 of  $\alpha$ -tubulin (Fig. 5); this binding site is the widely known colchicine site(28). In the MIL-tubulin structure, the A and B rings of MIL were buried deeply into the colchicine site, making key hydrophobic interactions with several residues of  $\beta$ -tubulin (Fig. 5C). Hydrogen bond formation between MIL and tubulin was not observed. Through comparison of the apo-(PDB:5XP3, 2.30Å resolution) and MIL-tubulin structures, we found that the Asn247 and Leu248 residues of T7 loop on  $\beta$ -tubulin occupied the colchicine site. This observation suggested that the T7 loop must shift outward for the MIL binding, as the Asn247 and Leu248 residues in apo collide with MIL in the MIL-tubulin complex (Fig. 5D). Similar conformational changes were also observed in the colchicine-tubulin complex (28,29). We also solved the structure of the colchicine-tubulin complex at 2.90 Å resolution (PDB:5XIW). Superimposition of the MIL-tubulin structure onto the colchicine-tubulin structure revealed that the C ring of MIL superimposes well with the C rings of colchicine (Fig. 6A and B). Similarly, the AB rings of MIL occupied the same pocket with the trimethoxybenzene of colchicine. However, colchicine interacts with  $\alpha$ -tubulin with a hydrogen bond while MIL shows no contacts with  $\alpha$ -tubulin (Fig. 6B). We also compared the binding model of MIL with that of SKLB028 and SKLB050. As indicated in Fig. 6C and D, SKLB028 and SKLB050 adopted identical positions and conformations as MIL, except that SKLB028 and SKLB050 interact with  $\alpha$ -tubulin through a hydrogen bond between the  $\alpha$ Thr179 residue and hydroxyl or amino. These results implied that linkage between compounds (SKLB028 and SKLB050) with residues on  $\alpha$ -tubulin may be the reason why SKLB028 and SKLB050 showed better activities than MIL.

***Chalcones with s-trans conformation are***

### *more active*

We compared the X-ray crystal structures of free MIL (CIF file of X-ray crystal structure of MIL is provided in the Supporting Information) with MIL in the tubulin complex. Interestingly, we found free MIL was in an *s-cis* conformation while MIL in the tubulin complex adopts an *s-trans* conformation (Fig. 7A, B and C), suggesting that the *s-trans* conformation of MIL might be the active component to bind to the colchicine site. To prove this hypothesis, we introduced an  $\alpha$ -methyl to SKLB028 and SKLB050 to obtain  $\alpha$ -M-SKLB028 and  $\alpha$ -M-SKLB050 (synthesis of  $\alpha$ -M-SKLB028 and  $\alpha$ -M-SKLB050 is described in the Supporting Information), which may mainly adopt *s-trans* conformations (Fig. 7D); this structural change is thought to be a result of steric repulsion which would exist between the introduced  $\alpha$ -methyl group and the A ring in the *s-cis* conformation. As expected,  $\alpha$ -M-SKLB028 and  $\alpha$ -M-SKLB050 were more active than SKLB028 and SKLB050 on five cancer cell lines (Fig. 7D and Table S1), respectively. Furthermore, we also observed that  $\alpha$ -M-SKLB050 could induce cell cycle arrest at a lower concentration (3 nM) compared to that of SKLB050 (30 nM) (Fig. S7). All these results implied that chalcones occupied the colchicine site in an *s-trans* conformational manner and that chalcones with *s-trans* conformation are more active.

### **Discussion**

Tubulin inhibitors are commonly used chemotherapeutic agents for cancer therapy (3,4,30). Most tubulin inhibitors used in clinical were targeted to paclitaxel or vinblastine sites, such as paclitaxel, docetaxel, vinblastine, vincristine, vinorelbine and eribulin (31-34). However, tubulin inhibitors binding to the colchicine site (the first discovered tubulin inhibitor site)(15,30) are not used in clinical cancer therapy(15). While, colchicine site tubulin inhibitor have obvious advantages over other tubulin inhibitors, such as having simple structure, being easy to synthesize; not being the substrate of multidrug-resistance protein and not easy to produce drug resistance(15).

Therefore, the development of colchicine tubulin inhibitors has good prospects.

In our present study, we reported a new class of chalcone tubulin inhibitors. Through modification of millepachine (a novel natural compound) we generated SKLB028 and SKLB050, which possess better activity. Through biotinylation of MIL and pull-down experiments, we successfully determined that the target of MIL and its derivatives is  $\beta$ -tubulin. Considering that MIL and its derivatives are tubulin depolymerization agents, we competed MIL with conventional tubulin depolymerization agents, colchicine and vinblastine, respectively, and found that MIL inhibits the binding of colchicine to tubulin. Therefore, the binding site of MIL was the colchicine site. Importantly, the crystal structure of the tubulin-MIL complex also proved this. As colchicine site tubulin inhibitors are not the substrate of multidrug-resistance proteins and not easy to produce drug resistance (15), we also tested the activity of MIL and its derivatives on three drug-resistant cell lines expressing high levels of MDR1 or MRP1 (A2780/T, HCT-8/T and HCT-8V). We found that SKLB028 and SKLB050 showed strong and similar growth inhibition against both sensitive and MDR cell lines, with a resistance factor ranging from 1.5 to 2.5, which supported the notion that colchicine site tubulin inhibitors are not the substrate of multidrug-resistance proteins.

Since the reversibility of the tubulin inhibitor binding to tubulin is an important parameter to determine the efficacy and toxicity of tubulin inhibitors *in vivo*(35), we also detected whether MIL and its derivatives bind irreversibly to tubulin. Through ultrafiltration and subsequent HPLC analysis, we found SKLB028 binds to tubulin in an irreversible way. Also, experiments at the cellular level showed that after a high dose of SKLB028 treatment for eight hours, the cellular morphology (indicated by tubulin staining) and cell cycle arrest could not recover by 72 h. However, the colcemid-treated cells could recover after only 24 h. All these data indicated that SKLB028 binds to tubulin in an irreversible way. Of note, all assays

here used to detect irreversible binding is indirect, because it is difficult to detect the irreversible binding directly when no covalent bond formed between MDs and tubulin.

Through comparison of the crystal structures of MIL-, SKLB028- and SKLB050-tubulin complexes, we observed that SKLB028 and SKLB050 bind to the colchicine site in a position almost the same as MIL, except that SKLB028 and SKLB050 interact with  $\alpha$ -tubulin through a hydrogen bond between the  $\alpha$ Thr179 residue and hydroxyl or amino groups (in the same way as colchicine interacts with  $\alpha$ Val181). This implied that linkage between these compounds (SKLB028 and SKLB050) and residues on  $\alpha$ -tubulin may be the reason why SKLB028 and SKLB050 showed better activities than MIL. Moreover, we also compared the X-ray crystal structures of free MIL with MIL in the tubulin complex. Interestingly, we found that free MIL was in an *s-cis* conformation, while MIL in the tubulin complex adopts an *s-trans* conformation, which suggested that the *s-trans* conformation was the active component. After the introduction of an  $\alpha$ -methyl group to SKLB028 and SKLB050 the activities of these compounds were clearly improved. These results showed that chalcones occupied the colchicine site in an *s-trans* conformational manner and that naturally occurring chalcones that have an *s-trans* conformation are more active.

In conclusion, we identified  $\beta$ -tubulin as the cellular target of MIL and its derivative, and showed that these compounds bind to the colchicine site in an irreversible manner. Importantly, we found that chalcone tubulin inhibitors with an *s-trans* dominant conformation were more active.

## Experimental procedures

### Reagents

Biotin, EBI (N,N'-ethylenebis(iodoacetamide)), colchicine, paclitaxel and colcemid were purchased from Selleck Chemicals. Penicillin, streptomycin, 4,6-diamidino-2-phenylindole (DAPI), MTT, DMSO and propidium iodide (PI) were obtained from Sigma. Purified porcine brain tubulin was

purchased from Cytoskeleton Inc. and supplied at 10 mg/ml in PEM buffer [80 mM PIPES (pH 6.9), 2 mM MgCl<sub>2</sub>, 0.5 mM EGTA and 1 mM GTP] and preserved at -80°C. Antibodies against  $\alpha$ -tubulin,  $\beta$ -tubulin, biotin, phosphorylation H3 (p-H3) and GAPDH were obtained from Santa Cruz Biotechnology. Anti- $\gamma$ -tubulin antibodies were obtained from Abcom. Anti-mouse secondary antibodies were from Zhongshanjinqiao Biotech. PIPES, EGTA, MgCl<sub>2</sub>, NaCl, glycerol and other conventional reagents were purchased from Kelun Pharmaceutical or Sangon Biotech. Cell lines and cell culture

Human ovarian carcinoma cells A780/S and A2780/T (resistant to paclitaxel), human hepatoma cells HepG2, and human colon cancer cells HCT-116, HCT-8 and HCT-8/V (resistant to vinblastine) were obtained from the American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640 or DMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100  $\mu$ g/mL streptomycin at 37 °C in an atmosphere of 5% CO<sub>2</sub>. All cells used here were tested and authenticated every year in our laboratory by using an AmpFISTR Identifier PCR Amplification Kit (Applied Biosystems), and the cells were last tested in October 2017.

### Pull-down of SKLB028-bound proteins

Biotin or Bio-SKLB028 (synthesis of Bio-SKLB028 described in supplementary information) was incubated with agarose beads (Dynabeads™ MyOne™ Streptavidin T1, Invitrogen) to obtain biotin-conjugated or Bio-SKLB028-conjugated agarose beads. HepG2 cells were harvested and lysed for 30 min in RIPA buffer (Beyotime Biotech) supplemented with protease and phosphatase inhibitors (Beyotime Biotech). After centrifugation at 12,000 x g for 30 min, the supernatant (4 mg/mL) was collected and equally divided into two parts, and then incubated with 0.1 ml of biotin- or biotin-adenanthin-beads in RIPA buffer overnight at 4 °C, respectively. After incubation, the beads were washed three times with RIPA buffer, and the bead-bound proteins were eluted, separated by SDS-PAGE, and visualized by

Coomassie brilliant blue staining or subjected to western blotting for  $\beta$ -tubulin and  $\alpha$ -tubulin. Also, the specific bands in the Bio-SKLB028 group were further identified by mass spectrometry, with the MS methods carried out rigorously following established laboratory protocols that were previously described(36).

#### ***Binding of SKLB028 to purified porcine tubulin***

Porcine brain tubulin (2  $\mu$ M) in PEM buffer [80 mM PIPES, (pH 6.9), 0.5 mM EGTA, 2 mM  $MgCl_2$ ] was pre-incubated with or without 20 or 200  $\mu$ M SKLB028 for 1 h before incubation with 2 or 20  $\mu$ M Bio-SKLB028 for another 2 h; 2 or 20  $\mu$ M biotin was incubated with tubulin for 2 h as control groups. Agarose beads were added to each sample and incubated for 15 min. The beads were then separated with centrifugation (12000 r.p.m., 5 min) and washed with RIPA buffer three times. Bead-bound proteins were detected by western blotting for  $\beta$ -tubulin. Also, total protein for each sample was detected by western blotting for  $\beta$ -tubulin as loading control. To do a time-dependent test, porcine brain tubulin (2  $\mu$ M) was incubated with 2  $\mu$ M Bio-SKLB028 for 0.5, 1 or 2 h. Biotin (2  $\mu$ M) was incubated with tubulin for 2 h as a control. The same pull-down assay using agarose beads was performed and the bead-bound proteins were detected by western blotting for  $\beta$ -tubulin. Also, total protein for each sample was detected by western blotting for  $\beta$ -tubulin as loading control.

#### ***Tryptophan-based binding assay***

The binding of small molecular to tubulin was detected using a tryptophan-based binding assay (25). Porcine brain tubulin (2  $\mu$ M) in PEM buffer containing 15% glycerol was incubated with 3.125, 6.25, 12.5, 25, 50, 100 or 200  $\mu$ M colchicine, MIL, SKLB028 or SKLB050 for 30min. The tryptophan fluorescence of the protein was then monitored at 295 nm (excitation) and 335 nm (emission) using a Biotech Gen5 spectrophotometer. Dissociation constants were calculated from fitting curves of decreasing fluorescence (DFL) using GraphPad Prism software.

#### ***Competition assay of SKLB028 with vinblastine or colchicine***

Porcine brain tubulin (1 $\mu$ M) in PEM buffer was pre-incubated with or without indicated concentrations of SKLB028, SKLB050, vinblastine or colchicine for 1 h before incubation with Bio-SKLB028 for a further 2 h. All samples were then extensively washed with PEM buffer three times and then cross-linked by a UV hybridization incubator (360 nm) for 10 min. Next, samples were mixed with loading buffer and denatured at 100 $^{\circ}$ C in a water bath for 10 min. Finally, samples were detected by western blotting using a biotin antibody. Total proteins were loaded to detect  $\beta$ -tubulin as a control.

#### ***Immunofluorescence staining***

HCT-8/V cells were seeded into 6-well plates and then treated with different compounds as indicated for 4 or 16 h. The cells were fixed with 4% paraformaldehyde and permeabilized with PBS containing 0.5% Triton X-100. After blocking for 30 min in 5% goat serum albumin at room temperature, cells were incubated with monoclonal antibodies (anti- $\beta$ -tubulin and anti- $\gamma$ -tubulin) at 4 $^{\circ}$ C for 12 h. The cells were then washed three times with PBS followed by incubation with fluorescent secondary antibodies and labeling of the nuclei with DAPI. Cells were finally washed three times and visualized using a fluorescence microscope (OLYMPUS, Tokyo, Japan).

#### ***In vitro tubulin polymerization assay***

Porcine tubulin (3 mg/mL) was re-suspended in PEM buffer with 15% glycerol and then pre-incubated with compounds or vehicle DMSO on ice. GTP was added to a final concentration of 1 mM before detecting the tubulin polymerization reaction. The reaction was monitored by measuring absorbance at 340 nm at 37  $^{\circ}$ C every minute in a Biotech Gen5 spectrophotometer.

#### ***Cell cycle analysis***

HCT-8/V cells were incubated with various concentrations of compounds for 16 h at 37  $^{\circ}$ C. The cells were then collected, washed with PBS, fixed in cold 70% ethanol overnight at 4  $^{\circ}$ C, washed again with PBS, and the DNA was stained for a minimum



of 10 min with 50  $\mu\text{g}/\text{mL}$  PI containing 1  $\text{mg}/\text{mL}$  of DNase-free RNaseA. The samples were then analyzed using a flow cytometer (B FACS Calibur).

#### ***Western blot detection of p-H3***

HCT-8/V cells were incubated with various compounds for 16 h at 37 °C. Cells were then harvested and lysed in RIPA buffer. Equal amounts (30  $\mu\text{g}$ ) of total proteins were loaded on a gel for SDS-PAGE, and after separation, proteins were transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes, which were subsequently blocked in 5% skim milk. The p-H3 antibody was diluted in blocking buffer and incubated with the membranes overnight at 4 °C. The membranes were then washed with PBST and incubated with secondary antibodies for 1 h. Immunoreactivity detection was accomplished using enhanced chemiluminescence reagents (Millipore). GAPDH was used as loading control.

#### ***EBI competition assay***

HCT-8/V cells were incubated with different compounds for 2 h, then 100  $\mu\text{M}$  EBI was added and the cells were incubated for another 2 h. Total proteins were lysed with RIPA buffer and subjected to western blot analysis for  $\beta$ -tubulin. The detailed western blot method is as shown above for p-H3 or as our previous study(26). GAPDH was employed as loading control.

#### ***HPLC detection of the binding of SKLB028 to tubulin***

Purified porcine tubulin was resuspended in PEM buffer. Then equal volumes (100 $\mu\text{L}$ ) of tubulin solution (3  $\text{mg}/\text{mL}$ ) were incubated with 30  $\mu\text{M}$  colcemid or 30  $\mu\text{M}$  SKLB028 for 1 h at room temperature before being transferred to an ultrafiltration tube (Millipore, 10KD) and centrifuged at 12000 rpm for 50 min at 4 °C. This ultrafiltration method could separate small molecule compounds from biomacromolecules (tubulin). After centrifugation, the filtrate was dried under vacuum and then dissolved in 200  $\mu\text{L}$   $\text{CH}_3\text{OH}$  to obtain a filtrate fraction. The tubulin (still in the ultrafiltration tube) was washed three times with

200  $\mu\text{L}$  PEM buffer (the PEM buffer was separated from tubulin also using an ultrafiltration method). The washed buffer was collected and dried under vacuum and then dissolved in 200  $\mu\text{L}$   $\text{CH}_3\text{OH}$  to get a tubulin fraction. The filtrate and tubulin fractions were then subjected to HPLC for detection of colcemid or SKLB028, respectively. Free colcemid (30  $\mu\text{M}$ ) or SKLB028 (30  $\mu\text{M}$ ) not incubated with tubulin were also dissolved in 200  $\mu\text{L}$   $\text{CH}_3\text{OH}$  and then detected by HPLC as controls, respectively.

#### ***Reversibility detection***

HCT-8/V cells were treated with high concentrations (10  $\mu\text{M}$ ) of SKLB028 or colcemid for 8 h, then were extensively washed to remove compounds, and were further cultured to 72 h. At 0, 8, 24, 48 and 72 h, tubulin morphology and cell cycle were analyzed by immunofluorescence and flow cytometry, respectively.

#### ***Structural biology***

Preparation of the crystals of the T2R-TTL complex (T2:  $\alpha\beta$ -tubulin heterodimer, R:the stathmin-like protein RB3, TTL: tubulin tyrosine ligase) were described in our previous study (36). To soak compounds into crystal, 0.1  $\mu\text{l}$  of the compound solution (10  $\text{mM}$  in DMSO) was added to the 2  $\mu\text{l}$  crystal-containing drop for 24 h at 20 °C. Beamlines BL17U1 or BL19U1 at Shanghai Synchrotron Radiation Facility were used to obtain X-ray diffraction data. Structure determination and refinement was the same as our previous study (36). PYMOL was used to generate the figures.

#### ***Acknowledgement***

This work was supported by grants from the National Natural Science Foundation of China (U1402222) and Guangdong Innovative Research Team Program (Grant 2011Y073)

#### ***Disclosure of Potential Conflicts of Interest***

None

## Reference

1. Perez, E. A. (2009) Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. *Molecular Cancer Therapeutics* **8**, 2086
2. Jordan, M. A., and Kamath, K. (2007) How do microtubule-targeted drugs work? An overview. *Current Cancer Drug Targets* **7**, 730
3. Bhalla, K. N. (2003) Microtubule-targeted anticancer agents and apoptosis. *Oncogene* **22**, 9075
4. Michaud, L. B. (2009) The epothilones: how pharmacology relates to clinical utility. *Annals of Pharmacotherapy* **43**, 1294
5. Kim, J. S., Lee, Y. C., Nam, H. T., Li, G., Yun, E. J., Song, K. S., Seo, K. S., Park, J. H., Ahn, J. W., and Zee, O. (2007) Apiculen A induces cell death through Fas ligand up-regulation and microtubule disruption by tubulin down-regulation in HM7 human colon cancer cells. *Clinical Cancer Research An Official Journal of the American Association for Cancer Research* **13**, 6509-6517
6. Kavallaris, M. (2010) Microtubules and resistance to tubulin-binding agents. *Nature Reviews Cancer* **10**, 194
7. Swain, S. M., and Arezzo, J. C. (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. *Clinical Advances in Hematology & Oncology H & O* **6**, 455-467
8. Fojo, A. T., and Menefee, M. (2005) Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). *Seminars in Oncology* **32**, 3-8
9. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. *Journal of the National Cancer Institute* **92**, 1295
10. Lockwood, A. H. (1979) Molecules in mammalian brain that interact with the colchicine site on tubulin. *Proceedings of the National Academy of Sciences of the United States of America* **76**, 1184
11. Moreland, L. W., and Ball, G. V. (1991) Colchicine and gout. *Arthritis & Rheumatism* **34**, 782
12. Sacks, S., Cordero, G., and Rojas, P. (1981) [Colchicine for familial Mediterranean fever (author's transl)]. *Revista Médica De Chile* **109**, 239
13. Imazio, M. (2014) Colchicine for pericarditis. *Trends in Cardiovascular Medicine* **25**, 129-136
14. Aktulga, E., Altaç M., Müftüoğlu, A., Ozyazgan, Y., Pazarlı, H., Tüzün, Y., Yalçın, B., Yazıcı, H., and Yurdakul, S. (1980) A double blind study of colchicine in Behcet's disease. *Haematologica* **65**, 399-402
15. Lu, Y., Chen, J., Xiao, M., Li, W., and Miller, D. D. (2012) An overview of tubulin inhibitors that interact with the colchicine binding site. *Pharmaceutical Research* **29**, 2943-2971
16. Buey, R. M., Calvo, E., Barasoain, I., Pineda, O., Edler, M. C., Matesanz, R., Cerezo, G., Vanderwal, C. D., Day, B. W., and Sorensen, E. J. (2007) Cyclostreptin binds covalently to microtubule pores and luminal taxoid binding sites. *Nature Chemical Biology* **3**, 117
17. Field, J. J., Pera, B., Calvo, E., Canales, A., Zurwerra, D., Trigili, C., Rodríguezsalarichs, J., Matesanz, R., Kanakkanthara, A., and Wakefield, S. J. (2012) Zampanolide, a potent new microtubule stabilizing agent, covalently reacts with the taxane luminal site in both tubulin  $\alpha,\beta$ -heterodimers and microtubules. *Chemistry & Biology* **19**, 686
18. Prota, A. E., Bargsten, K., Zurwerra, D., Field, J. J., Díaz, J. F., Altmann, K. H., and Steinmetz, M. O. (2013) Molecular mechanism of action of microtubule-stabilizing anticancer agents. *Science* **339**, 587
19. Shan, B., Medina, J. C., Santha, E., Frankmoelle, W. P., Chou, T., Learned, R. M., Narbut, M. R., Stott, D., Wu, P., and Jaen, J. C. (1999) Selective, covalent modification of 尾-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. *Proceedings of the National Academy of Sciences of the United States of America* **96**, 5686-5691
20. Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., Zheng, W., Seletsky, B. M., Zhu, X., Lewis, B.

M., Kishi, Y., Yu, M. J., and Littlefield, B. A. (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. *Cancer research* **71**, 496-505

21. Ye, H., Fu, A., Wu, W., Li, Y., Wang, G., Tang, M., Li, S., He, S., Zhong, S., and Lai, H. (2012) Cytotoxic and apoptotic effects of constituents from *Milletia pachycarpa* Benth. *Fitoterapia* **83**, 1402-1408

22. Wu, W., Ye, H., Wan, L., Han, X., Wang, G., Hu, J., Tang, M., Duan, X., Fan, Y., and He, S. (2013) Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. *Carcinogenesis* **34**, 1636-1643

23. Cao, D., Han, X., Wang, G., Yang, Z., Peng, F., Ma, L., Zhang, R., Ye, H., Tang, M., and Wu, W. (2013) Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents. *European Journal of Medicinal Chemistry* **62**, 579-589

24. Yang, Z., Wu, W., Wang, J., Liu, L., Li, L., Yang, J., Wang, G., Cao, D., Zhang, R., and Tang, M. (2014) Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors. *Journal of Medicinal Chemistry* **57**, 7977

25. Chinen, T., Liu, P., Shioda, S., Pagel, J., Cerikan, B., Lin, T., Gruss, O., Hayashi, Y., Takeno, H., and Shima, T. (2015) The  $\gamma$ -tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle. *Nature Communications* **6**, 8722

26. Cao, D., Liu, Y., Yan, W., Wang, C., Bai, P., Wang, T., Tang, M., Wang, X., Yang, Z., and Ma, B. (2016) Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors. *Journal of Medicinal Chemistry* **59**, 5721

27. Prota, A. E., Bargsten, K., Northcote, P. T., Marsh, M., Altmann, K. H., Miller, J. H., D áz, J. F., and Steinmetz, M. O. (2014) Structural basis of microtubule stabilization by laulimalide and peloruside A. *Angewandte Chemie* **53**, 1621-1625

28. Wei, W., Ayad, N. G., Wan, Y., Zhang, G. J., Kirschner, M. W., and Kaelin, W. G., Jr. (2004) Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. *Nature* **428**, 194-198

29. Dorláns, A., Gigant, B., Ravelli, R. B. G., Mailliet, P., Mikol, V., Knossow, M., and McIntosh, J. R. (2009) Variations in the Colchicine-Binding Domain Provide Insight into the Structural Switch of Tubulin. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 13775-13779

30. Nakagawa-Goto, K., Oda, A., Hamel, E., Ohkoshi, E., Lee, K. H., and Goto, M. (2015) Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring. *Journal of Medicinal Chemistry* **58**, 2378-2389

31. Clegg, A., Scott, D., Hewitson, P., Sidhu, M., and Waugh, N. (2002) Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. *Thorax* **57**, 20-28

32. Wiczorek, M., Tcherkezian, J., Bernier, C., Prota, A. E., Chaaban, S., Rolland, Y., Godbout, C., Hancock, M. A., Arezzo, J. C., and Ocal, O. (2016) The synthetic diazamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. *Science Translational Medicine* **8**, 365ra159

33. Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Di éas, V., and Delozier, T. (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet* **377**, 914

34. Doodhi, H., Prota, A., Rodr íguez-Garc ía, R., Xiao, H., Custar, D., Bargsten, K., Katrukha, E., Hilbert, M., Hua, S., and Jiang, K. (2016) Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes. *Current Biology Cb* **26**, 1713

35. Thomas, N. E., Thamkachy, R., Sivakumar, K. C., Sreedevi, K. J., Louis, X. L., Thomas, S. A., Kumar,

R., Rajasekharan, K. N., Cassimeris, L., and Sengupta, S. (2014) Reversible action of diaminothiazoles in cancer cells is implicated by the induction of a fast conformational change of tubulin and suppression of microtubule dynamics. *Molecular Cancer Therapeutics* **13**, 179-189

36. Yang, J., Wang, Y., Wang, T., Jiang, J., Botting, C. H., Liu, H., Chen, Q., Yang, J., Naismith, J. H., and Zhu, X. (2016) Pironetin reacts covalently with cysteine-316 of  $\alpha$ -tubulin to destabilize microtubule. *Nature Communications* **7**, 12103

**Table 1. MTT assay was used to detect the IC<sub>50</sub> (half maximal inhibitory concentration) values of MDs, Bio-SKLB028 on HepG2, A2780s cells, data was expressed as mean ± SD.**

	IC50(nM)±SD			
	MIL	SKLB028	SKLB050	Bio-SKLB028
HepG2	2300±220	120±12	31±2	298±31
A2780S	3509±572	89±7	60±4	159±12

**Table2. Verification of activities of taxol, vinblastine, SKLB028, SKLB050 on A2780S, A2780 / T, HCT-8, HCT-8 / V and HCT-8 / T cells. MTT assay was used to detect the IC<sub>50</sub> (half maximal inhibitory concentration) values, data was expressed as mean ± SD.**

Cell lines	IC <sub>50</sub> (nM)±SD				
	A2780S	A2780/T	HCT-8	HCT-8/V	HCT-8/T
Paclitaxel	46±5	8600±1000(186)*	36±6	9200±430(255)	10800±670(300)
Vinblastine	33±7	7540±876(225)	27±3	9800±670(362)	19800±1200(733)
SKLB028	72±8	150±19(2.1)	98±11	134±13(1.4)	201±56(2.1)
SKLB050	23±4	35±5(1.5)	13±2	19±1(1.5)	33±5(2.5)

\*The numbers in parentheses are the calculated relative resistance values, obtained by dividing the IC<sub>50</sub> value of the resistant line by the IC<sub>50</sub> value of the parental line

**Table 3. Data collection and refinement statistics.**

Ligand (PDB code)	SKLB028 (5YL2)	Colchicine(5XIW)	MIL(5YLJ)	SKLB050(5YLS)	apo (5XP3)
<b>Data collection statistics</b>					
X-ray source	SSRF-BL17U1	SSRF-BL17U1	SSRF-BL17U1	SSRF-BL17U1	SSRF-BL19U1
Wavelength (Å)	0.97845	0.97845	0.97845	0.97845	0.97845
Resolution range (Å)	50.0–2.09(2.15–2.09)	50.0–2.90(2.98–2.90)	50–2.70(2.77–2.70)	50–3.00 (3.07–3.00)	50.0–2.30(2.37–2.30)
Space group	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>
Unit cell: a,b,c (Å)	105.542, 158.199, 181.797	105.491, 159.148, 181.702	105.231, 157.367, 182.684	105.767, 159.054, 183.151	105.168,157.964, 181.408
Total reflections	1,034,053	441,140	507,371	415,606	881,784
Unique reflections	106,543(7,060)	65,289 (5,379)	86,475(6,924)	62,464(4,106)	133,224(10,957)
Redundancy	6.7(6.6)	6.8 (7.0)	6.8(6.6)	6.7(6.8)	6.6(6.5)
Completeness (%)	100(100)	100 (100)	100(99.9)	100(100)	100 (100)
Mean I/sigma (I)	18.62(2.25)	14.4 (2.25)	13.75(2.25)	15.90(2.25)	19.50(2.31)
Rmerge	0.094( 0.588)	0.164 (0.715)	0.132(0.695)	0.120(0.673)	0.081(0.662)
<b>Refinement statistics</b>					
R-work/R-free	0.208/0.253	0.204/0.253	0.216/0.256	0.208/0.252	0.189/0.24
RMSD bond length (Å)	0.008	0.008	0.007	0.007	0.012
RMSD bond angle (°)	1.314	1.26	1.228	1.239	1.57
<b>Ramachandran plot statistics</b>					
Favored regions (%)	97.6	97	98.1	98	97.6
Additional allowed regions (%)	2.3	2.68	1.8	1.8	2.1
Disallowed regions (%)	0	0.32	0.1	0.2	0.3

Figures/Figure legends




Figure 1: MIL directly targets  $\beta$ -Tubulin. (A) Chemical structures of MIL. (B) HepG2 cell lysates were incubated with Bio-SKLB028 or biotin, followed by pull-down with streptavidin-agarose. The precipitates were resolved by SDS-PAGE, and the gel was stained with coomassie staining. (C) HepG2 cell lysates were incubated with Bio-SKLB028 or biotin, followed by pull-down with streptavidin-agarose. the precipitates were detected by western blot by  $\alpha$ - and  $\beta$ -tubulin. (D) Porcine brain tubulin(1 $\mu$ M) were pre-incubated with or without indicated concentrations of SKLB028 for 2h before incubation with lower concentration of Bio-SKLB028 for another 2hours, different concentrations of biotin was incubated with tubulin for 2 hours as control groups. Then all the samples were pulled down by a streptavidin-agarose beads and the eluted samples were bolted for  $\beta$ -tubulin. Also, total protein for each sample were detected by western blot for  $\beta$ -tubulin as loading control. (E) Porcine brain tubulin(1 $\mu$ M) were incubated with Bio-SKLB028 for different times, and then pulled down by a streptavidin-agarose beads and the eluted samples were bolted for  $\beta$ -tubulin. Also, total protein for each sample were detected by western blot for  $\beta$ -tubulin as loading control. (F) Tryptophan-based binding assay to detect the  $K_d$  value of indicated compounds binding to tubulin: Indicated compounds at different concentrations (3.125, 6.25, 12.5, 25, 50, 100, 200 $\mu$ M) were incubated with tubulin for 30min then monitored at 295 nm (excitation) and 335nm (emission) using Biotech Gen5 spectrophotometer. Dissociation constants were calculated from fitting curves of decreasing fluorescence (DFL) using the GraphPad Prizm software. Col, colchicine; MIL, millepachine.  $\alpha$ -Tub,  $\alpha$ -tubulin;  $\beta$ -Tub,  $\beta$ -tubulin; Col, colchicine; MIL, millepachine.






Figure 2: MDs inhibit tubulin polymerization and cause G2/M phase cell cycle arrest. (A) HCT-8/V cells were treated with 1 $\mu$ M MIL, 50nM SKLB050, 50nM colchicine or 50nM paclitaxel for 16hours, or treated with 50nM or 200nM SKLB028 for 4hours or 16hours. then tubulin morphology was detected by immunofluorescence with anti- $\beta$ -tubulin and DAPI staining. Bar:10 $\mu$ m. (B) Indicated concentrations of compounds were co-incubated with tubulin (3mg/ml) at 37 $^{\circ}$ C, absorbance at 340 nm were detected every one minutes for 30 minutes. (C) HCT-8/V cells were incubated with 1 $\mu$ M MIL, 50nM SKLB050, 50nM colchicine or 100nM SKLB028 for 16hours, then cell lysates were collected and subjected to western blot for p-H3 detection, GAPDH was used as loading control. (D) HCT-8/V cells were incubated with 1 $\mu$ M MIL, 50nM SKLB050, 50nM colchicine 100nM for 16hours, then subjected to PI staining and analyzed by a flow cytometer for cell cycle analysis. Col, colchicine; MIL, millepachicine; Tax, paclitaxel.




Figure 3: MDs bind to colchicine site of  $\beta$ -tubulin. (A) Porcine brain tubulin(1 $\mu$ M) were treated with 1 $\mu$ M SKLB028, 1 $\mu$ M vinblastine, 10 $\mu$ M vinblastine, 1 $\mu$ M colchicine, 10 $\mu$ M colchicine or 1 $\mu$ M SKLB050 for 1hour before treated with 1 $\mu$ M Bio-SKLB028 for another 2hours. After totally wash of unbounded compounds and cross-linked by a UV hybridization incubator for 10min, samples were blotted for biotin. Total proteins were blotted for  $\beta$ -tubulin as loading control. (B) HCT-8/Vcells were incubated with or without indicated concentrations of MDs for 2 hours, then 100 $\mu$ M EBI were added to cells and incubated for another 2 hours. Total protein were lysed with RIPA lysis buffer and subjected to western blot analysis for  $\beta$ -tubulin and GAPDH. Vin, vinblastine; Col, colchicine; MIL, millepachicine;  $\beta$ -Tub,  $\beta$ -tubulin; EBI: N,N'-ethylenebis(iodoacetamide).




Figure 4: MDs bind irreversibly to  $\beta$ -tubulin. (A) Tubulin (3mg/ml) incubated with 30 $\mu$ M colcemid or 30 $\mu$ M SKLB028 for 1h. Then tubulin part and filtrate part were separated with an ultrafiltration method. Compounds in tubulin part and filtrate part were detected by HPLC. Colcemid (30 $\mu$ M) or SKLB028 (30 $\mu$ M) dissolved in 200 $\mu$ L CH<sub>3</sub>OH were also detected by HPLC as controls. This experiment was repeated three times. (B) High concentrations (10 $\mu$ M) of SKLB028 or colcemid were co-incubated with HCT-8/V cells for 8hours and then compounds were extensively washed for three times, cells were further cultured to 72hours. At 0h, 8h, 24h, 48h, 72h points, tubulin morphology were analyzed by immunofluorescence. Bar:20 $\mu$ m.




Figure 5: Structure of the MIL-T2R-TTL complex. (A) Chemical structure of MIL. (B) Overall view of the complex formed between  $\alpha\beta$ -tubulin and MIL. (C) Close-up views of the interaction network observed between MIL (green sticks) and tubulin (black cartoon). Interacting residues of tubulin are shown in stick representation. Oxygen atoms are colored red and blue. (D) Superimposition of the MIL-T2R-TTL (cyan cartoon) and apo-T2R-TTL (black cartoon) structures. MIL is in green stick representation. Black arrows highlight regions of steric clashes between tubulin and MIL, purple arrow shows the large main chain changes between apo- from MIL-complex.




Figure 6: Comparison the binding modes of MIL- and colchicine-, MIL- and SKLB028-, MIL- and SKLB050-T2R-TTL complex. (A) Chemical structure of colchicine. (B) Superimposition of the MIL-T2R-TTL (gray cartoons) and colchicine-T2R-TTL (purple cartoons) structures. MIL and colchicine are in green and purple stick representation, respectively. (C) Superimposition of the MIL-T2R-TTL (green cartoons) and SKLB028-T2R-TTL (purple cartoons) structures. MIL and SKLB028 are in red and green stick representation, respectively. (D) Superimposition of the MIL-T2R-TTL (green cartoons) and SKLB050-T2R-TTL (paleyellow cartoons) structures. MIL and SKLB050 are in red and green stick representation, respectively. MIL, millepachine.




Figure 7: Chalcones with *s-trans* conformation are more active. **(A)** X-ray structure of free MIL. **(B)** Stereo views of MIL in tubulin with the final refined 2Fo–Fc electron density contoured at 0.5, 1, 1.5 and 2 $\sigma$ . **(C)** Structural formula of free MIL(*s-cis*) and MIL(*s-trans*) in tubulin complex. **(D)** Chemical structures of MDs and their average  $IC_{50}$ s on five cancer cells (A2780S, A2780/T, HCT-8, HCT-8/V, HCT-8/T, original data shown in table S1 ). MIL, millepachine.

**The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in  $\beta$ -tubulin**

Yang Jianhong, Yan Wei, Yu Yamei, Wang Yuxi, Yang Tao, Xue Linlin, Yuan Xue, Long Caofeng, Liu Zuowei, Chen Xiaoxin, Hu Mengshi, Zheng Li, Qiu Qiang, Pei Heying, Li Dan, Wang Fang, Bai Peng, Wen Jiaolin, Ye Haoyu Sr. and Chen Lijuan

*J. Biol. Chem.* published online April 24, 2018

---

Access the most updated version of this article at doi: [10.1074/jbc.RA117.001658](https://doi.org/10.1074/jbc.RA117.001658)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts